Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment

被引：0

作者：

Hekman, Lauren ^{[1
]}

Napierkowski, Eva ^{[1
]}

Hartman, Natalie C. ^{[1
]}

Ellis, Jeffrey L. ^{[1
]}

Wagner, Robert H. ^{[2
]}

Bova, Davide ^{[3
]}

Picken, Maria M. ^{[4
]}

Flanigan, Robert C. ^{[1
]}

机构：

[1] Loyola Univ Med Ctr, Dept Urol, Maywood, IL 60153 USA

[2] Loyola Univ Med Ctr, Dept Nucl Med, Maywood, IL USA

[3] Loyola Univ Med Ctr, Dept Radiol, Maywood, IL USA

[4] Loyola Univ Med Ctr, Dept Pathol, Maywood, IL USA

来源：

CASE REPORTS IN SURGERY | 2023年 / 2023卷

关键词：

COMPUTED-TOMOGRAPHY; F-18-FDG PET/CT; GA-68-PSMA;

D O I：

10.1155/2023/1458175

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can also identify other malignancies. 18F-PSMA PET has not been studied as a potential tool for hepatocellular carcinoma (HCC). We describe the case of a 76-year-old male with a rising prostate-specific antigen (PSA) after definitive prostate cancer treatment and no prior liver pathology who was incidentally found to have HCC on 18F-PSMA PET.

引用

页数：5

共 50 条

[21] Clinical utility and impact on the therapeutic management of PET 18F-PSMA DCFPyL in prostate cancer
Amorelli, Francesco
Plaza, Pedro J.
Torices, Jose M.
Natali, Augusto O.
Martinez, Alvaro
Sanz, Javier
Membrive, Ismael
Algara, Manuel
Foro, Palmira
RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2435 - S2436
[22] Management impact and detection rate of 18F-Prostate-Specific Membrane Antigen (18F-PSMA) PET/CT imaging for biochemically recurrent prostate cancer
Panagiotidis, E.
Paschali, A.
Klampatsas, A.
Pipintakou, A.
Makridou, A.
Chatzipavlidou, V.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S174 - S174
[23] 18F-FDG or 68Ga/18F-PSMA PET/CT in recurrent renal cancer?
Laura Evangelista
Lea Cuppari
Clinical and Translational Imaging, 2018, 6 : 329 - 330
[24] 18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence
Marafi, Fahad
Sasikumar, Arun
Fathallah, Wael
Esmail, Abdulredh
CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : E61 - E62
[25] 18F-FDG or 68Ga/18F-PSMA PET/CT in recurrent renal cancer?
Evangelista, Laura
Cuppari, Lea
CLINICAL AND TRANSLATIONAL IMAGING, 2018, 6 (04) : 329 - 330
[26] Role of 68Ga/18F-PSMA PET/CT in the Secondary Staging of Prostate Cancer patients as a guide for clinicians
Mammucci, P.
Ferrari, C.
Lavelli, V.
Battisti, C.
Merenda, N. C.
Rubini, G.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S533 - S534
[27] More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT
Pianou, Nikoletta K.
Stavrou, Petros Z.
Vlontzou, Evangelia
Rondogianni, Phivi
Exarhos, Demetrios N.
Datseris, Ioannis E.
HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2019, 22 (01): : 6 - 9
[28] Clinical outcomes after treatment following the use of 18F-PSMA PET/CT scans in patients with recurrent prostate cancer
Rodriguez-Rubio Corona, J.
Canete Sanchez, F.
Santaella Guardiola, Y.
Pinero Fernandez-Reyes, M.
Quintana Bolano, C.
Pajares Vinardell, M.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S651 - S651
[29] Impact of the 18F-PSMA PET/CT in the evaluation of response to androgen deprivation therapy in prostate cancer, a single center experience
Medina-Ornelas, S.
Garcia-Perez, F.
Alvarez-Avitia, M.
Sobrevilla-Moreno, N.
Jimenez-Rios, M.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S529 - S529
[30] Case Report: 18F-PSMA PET/CT May Improve the Clinical Management of Penile Metastases From Prostate Cancer
Fan, Junjie
Liang, Hua
Zhang, Xing
Chen, Xingfa
Duan, Xiaoyi
Li, Lei
He, Dalin
Wu, Kaijie
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →